文献速递淋巴瘤造血干细胞移植与细胞治疗

靶向LMP1抗原的嵌合抗原受体T细胞的功能研究

[Functional investigation of chimeric antigen receptor T cells targeting LMP1 antigen].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

本研究构建靶向LMP1抗原的CAR-T细胞,体外验证其对EBV阳性淋巴瘤细胞的特异性杀伤、脱颗粒、活化及细胞因子分泌作用,感染效率大于80%,杀伤具LMP1特异性但细胞因子差异未达统计学显著。

要点

  • 成功构建LMP1 CAR慢病毒载体并感染人T细胞,感染效率大于80%。
  • LMP1 CAR-T细胞在效靶比4∶1共培养48 h后对Raji细胞杀伤增强,对Ramos无明显杀伤。
  • 与LMP1阳性淋巴瘤细胞共培养后脱颗粒和活化增强,细胞因子分泌高于Vector-T组但未达统计学显著。

核心结论

  • EBV阳性淋巴瘤细胞表面可特异表达LMP1蛋白。
  • 成功获得LMP1 CAR-T细胞,体外可特异杀伤LMP1阳性淋巴瘤细胞,脱颗粒和活化效应增强,具潜在临床应用前景。

研究设计与样本

  • 应用分子克隆技术构建二代LMP1 CAR表达质粒,通过慢病毒包装体系感染人T细胞获得LMP1 CAR-T细胞。
  • 体外实验验证LMP1 CAR-T细胞对感染EBV后的LMP1阳性淋巴瘤细胞的特异性细胞毒性作用。

主要发现

  • LMP1蛋白表达于EBV阳性的淋巴瘤细胞表面。
  • 感染效率大于80%。
  • 效靶比4∶1共培养48 h后,LMP1 CAR-T细胞对Raji细胞杀伤作用增强,对Ramos细胞无明显杀伤作用。
  • 1∶1共培养5 h后,CD107a(+) T细胞比例LMP1 CAR-T组(13.25±2.94)% vs Vector-T组(1.55±0.05)%,t=3.972,P=0.017。
  • 共培养后CD69(+) T细胞比例LMP1 CAR-T组(7.40±0.41)% vs Vector-T组(3.48±0.47)%,t=6.268,P=0.003;CD25(+) T细胞比例LMP1 CAR-T组(73.00±4.73)% vs Vector-T组(57.67±2.60)%,t=2.842,P=0.047。

临床怎么用

  • 原文结论为LMP1 CAR-T细胞具潜在临床应用前景,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study aimed to create a type of CAR-T cells that targets LMP1 antigen and study its immunotherapeutic effect on LMP1-positive hematological malignancies. Methods: To generate LMP1 CAR-T cells, a plasmid expressing LMP1 CAR was created using molecular cloning technology, and T cells were infected with LMP1 CAR lentivirus. The effects of LMP1 CAR-T cells on specific cytotoxicity against LMP1-positive tumor cell lines infected with the EB virus had been confirmed. Results: ① LMP1 protein expressing on EB virus-positive lymphoma cells surface was verified. ② The LMP1 CAR-expressing plasmid was created, and LMP1 CAR-T cells were obtained by infecting T cells with a lentivirus packaging system, with an infection efficiency of more than 80% . ③LMP1 CAR-T cells have a 4∶1 effect-to-target ratio in killing LMP1-positive lymphoma cells. The killing effect of LMP1 CAR-T cells on Raji cells was enhanced after 48 h of coculture, but there was no significant killing effect on Ramos, which are LMP1-negative lymphoma cells. ④After coculture with LMP1-positive lymphoma cells at a ratio of 1∶1 for 5 h, the degranulation effect was enhanced. The proportion of CD107a(+) T cells in the LMP1 CAR-T cell treatment group was significantly higher than that in the vector-T cell group [ (13.25±2.94) % vs (1.55±0.05) % , t=3.972, P=0.017]. ⑤After coculture with LMP1-positive lymphoma cells, the proportion of CD69(+) and CD25(+) T cells in the LMP1 CAR-T cell group was significantly higher than that in vector-T cell group [ (7.40±0.41) % vs (3.48±0.47) % , t=6.268, P=0.003; (73.00±4.73) % vs (57.67±2.60) % , t=2.842, P=0.047]. ⑥After coculture with LMP1-positive lymphoma cells, cytokine secretion in the LMP1 CAR-T cell group was higher than that in the vector-T cell group [interferon-gamma: (703±73) ng/L vs (422±87) ng/L, t=2.478, P=0.068; tumor necrosis factor-alpha: (215±35) ng/L vs (125±2) ng/L, t=2.536, P=0.064]. Conclusion: In this study, we found that the LMP1 protein is only found on the surface of the EBV-positive tumor cell. Simultaneously, we created an LMP1 CAR-expressing plasmid and obtained LMP1 CAR-T cells by infecting T cells with a lentivirus packaging system. Furthermore, we demonstrated that LMP1 CAR-T cells could specifically kill LMP1-positive tumor cells in vitro. The degranulation and activation effects of LMP1 CAR-T cells were enhanced after coculture with LMP1-positive tumor cells, indicating a potential clinical application. 目的: 制备一种靶向LMP1抗原的嵌合抗原受体T细胞(CAR-T细胞),研究其对EB病毒(EBV)阳性淋巴瘤的免疫治疗作用。 方法: 应用分子克隆技术构建二代LMP1 CAR表达质粒,通过慢病毒包装体系包装病毒后感染人T细胞,获得LMP1 CAR-T细胞,体外实验验证LMP1 CAR-T细胞对感染EBV后的LMP1阳性淋巴瘤细胞的特异性细胞毒性作用。 结果: ①LMP1蛋白表达于EBV阳性的淋巴瘤细胞表面;②成功构建了二代LMP1 CAR慢病毒载体,感染人T细胞,获取LMP1 CAR-T细胞,感染效率大于80%;③LMP1 CAR-T细胞可特异性杀伤LMP1阳性淋巴瘤细胞,当效靶比按4∶1共培养48 h后,LMP1 CAR-T细胞对Raji细胞的杀伤作用增强,对Ramos细胞无明显杀伤作用;④与LMP1阳性淋巴瘤细胞按1∶1共培养5 h后,LMP1 CAR-T细胞处理组CD107a(+) T细胞比例显著高于Vector-T细胞组[(13.25±2.94)%对(1.55±0.05)%,t=3.972,P=0.017],脱颗粒效果增强;⑤与LMP1阳性淋巴瘤细胞共培养后,LMP1 CAR-T细胞组CD69(+)、CD25(+) T细胞比例显高于Vector-T细胞组[(7.40±0.41)%对(3.48±0.47)%,t=6.268,P=0.003;(73.00±4.73)%对(57.67±2.60)%,t=2.842,P=0.047],活化效应增强。⑥与LMP1阳性淋巴瘤细胞共培养后,LMP1 CAR-T细胞组细胞因子分泌增强,高于Vector-T细胞组[IFN-γ:(703±73)ng/L对(422±87)ng/L,t=2.478,P=0.068;TNF-α:(215±35)ng/L对(125±2)ng/L,t=2.536,P=0.064]。 结论: 该研究证实EBV阳性淋巴瘤细胞表面可特异表达LMP1蛋白,成功构建了LMP1 CAR慢病毒载体并感染人T细胞,成功获得LMP1 CAR-T细胞。体外实验证实:与LMP1阳性淋巴瘤细胞共培养后,LMP1 CAR-T细胞脱颗粒效果增强,活化效应增强,高效分泌细胞因子,可特异杀伤LMP1阳性淋巴瘤细胞,具有潜在的临床应用前景。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. He HZ, Xing YY, Zhang Y, et al. [Functional investigation of chimeric antigen receptor T cells targeting LMP1 antigen]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35405781. doi:10.3760/cma.j.issn.0253-2727.2022.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。